Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids

References

• World Health Organization. Global health estimates: life expectancy and leading causes of death and disability 2019. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. Accessed August 25, 2022.
   Google Scholar
• Taiwan Ministry of Health and Welfare. 2020 Cause of death statistics. Available from: https://www.mohw.gov.tw/lp-5256-2.html. Accessed August 25, 2022.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Diseases; 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed August 25, 2022.
   Google Scholar
• Parkin L, Barson D, Zeng J, Horsburgh S, Sharples K, Dummer J. Patterns of use of long-acting bronchodilators in patients with COPD: a nationwide follow-up study of new users in New Zealand. Respirology. 2018;23:583–592.
   PubMed Web of Science ®Google Scholar
• Price D, Miravitlles M, Pavord I, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med. 2016;26:16061.
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Brusselle G, Jones R, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world study. NPJ Prim Care Respir Med. 2016;26:16002.
   PubMed Web of Science ®Google Scholar
• Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145:1286–1297.
   PubMed Web of Science ®Google Scholar
• Chen H, Sun J, Huang Q, et al. Inhaled corticosteroids and the pneumonia risk in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Front Pharmacol. 2021;12:691621.
   PubMedGoogle Scholar
• Lee SH, Lee JH, Yoon HI, et al. Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respir Res. 2019;20:62.
   PubMed Web of Science ®Google Scholar
• Roche N, Aguilaniu B, Li PZ, Hess D; COLIBRI collaborators. Trends over time in COPD treatment choices by respiratory physicians: an analysis from the COLIBRI-COPD French cohort. Respir Med. 2019;156:8–14. doi:10.1016/j.rmed.2019.07.023
   PubMed Web of Science ®Google Scholar
• Bloom CI, Elkin SL, Quint JK. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016. Int J Chron Obstruct Pulmon Dis. 2019;14:279–287. doi:10.2147/COPD.S190086
   PubMed Web of Science ®Google Scholar
• Parkin L, Khuu W, Stanbrook MB, Tadrous M, Martins D, Gomes T. Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: a population-based study. Respir Med. 2018;143:1–7. doi:10.1016/j.rmed.2018.08.001
   PubMed Web of Science ®Google Scholar
• National Health Insurance Administration. 2021-2022 National Health Insurance Annual Report. Available from: https://www.nhi.gov.tw/Content_List.aspx?n=9223A12B5B31CB37&topn=4864A82710DE35ED. Accessed August 25, 2022.
   Google Scholar
• Lin LY, Warren-Gash C, Smeeth L, Chen PC. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol Health. 2018;40:e2018062. doi:10.4178/epih.e2018062
   PubMed Web of Science ®Google Scholar
• Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD. 2009;6:388–394.
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Mamdani M, Sykora K, Li P, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960–962.
   PubMedGoogle Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–3107.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Marco FD, Blasi F, et al. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: a network meta-analysis. Pulm Pharmacol Ther. 2019;59:101855.
   PubMed Web of Science ®Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066.
   PubMed Web of Science ®Google Scholar
• Quint JK, Montonen J, Esposito DB, et al. Effectiveness and safety of COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS in a US claims database. Adv Ther. 2021;38:2249–2270.
   PubMed Web of Science ®Google Scholar
• Wang MT, Lai JH, Huang YL, et al. Comparative effectiveness and safety of different types of inhaled long-acting β2-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β2-agonist plus inhaled corticosteroid fixed-dose combinations in COPD: a propensity score-inverse probability of treatment weighting cohort study. Chest. 2021;160:1255–1270.
   PubMed Web of Science ®Google Scholar
• Sharif R, Cuevas CR, Wang Y, Arora M, Sharma G. Guideline adherence in management of stable chronic obstructive pulmonary disease. Respir Med. 2013;107:1046–1052.
   PubMed Web of Science ®Google Scholar
• Desalu OO, Onyedum CC, Adeoti AO, et al. Guideline-based COPD management in a resource-limited setting - physicians’ understanding, adherence and barriers: a cross-sectional survey of internal and family medicine hospital-based physicians in Nigeria. Prim Care Respir J. 2013;22:79–85.
   PubMedGoogle Scholar
• Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M. Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: results from an Observational Cross-Sectional Physician and Patient Survey. Int J Chron Obstruct Pulmon Dis. 2022;17:749–761.
   PubMed Web of Science ®Google Scholar
• Moretz C, Sharpsten L, Bengtson LG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737.
   PubMed Web of Science ®Google Scholar
• Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA. Comparative effectiveness of long-acting beta2 -agonist combined with a long-acting muscarinic antagonist or inhaled corticosteroid in chronic obstructive pulmonary disease. Pharmacotherapy. 2017;37:447–455.
   PubMed Web of Science ®Google Scholar